Fig. 1: SARS-CoV-2-specific antibody response after mRNA vaccination of healthy individuals and autoimmune patients.
From: SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
A Yale HCW: 2 doses mRNA vaccine; plasma collected at: pre dose 1—just prior to vaccination; d7—7 days post dose 1; pre dose 2—just prior to dose 2, approximately 21–28 days post dose 1; d7 pd2—day 7 post dose 2; d28 pd2—day 28 post dose 2. BRI: 2 doses mRNA vaccine; plasma collected at pre dose 1—prior to vaccination; d14 pd2—day 14 post dose 2; d90 pd2—day 90 post dose 2. CoronaVac Booster: 1 dose mRNA vaccine >4 weeks after 2 doses CoronaVac. Plasma collected at pre-Booster—prior to vaccination; d28—day 28 post booster. Longitudinal Control cohort: Unvaccinated participants; plasma collected at d0—day 0; d7—day 7; d30—day 30; d60—day 60; d90—day 90; d120—day 120) B–D CoV-2-RBD REAP score for each patient pre-vaccine to post-vaccine in the Yale HCW, CoronaVac Booster, and BRI cohorts, respectively. Each pair of dots represents a single individual. E, F CoV-2-RBD REAP score (E) and SARS-CoV-2 neutralization capacity (F) at the final time point. Significance was assessed by one-way ANOVA (p = 2.45E − 7 (E), p = 2.81E − 6 (F), with post hoc testing performed using Dunnett’s test to compare the mean of every column with healthy control (CD20 vs. Control: p = 5.1E − 8 (E), CTLA4 vs. Control: p = 0.0145 (E); CD20 vs. Control: p = 1.35E − 7 (F), TNF/DM vs. Control: p = 0.034 (F). Boxplot box depicts the 25th to 75th percentile of the data, the middle line represents the median, and upper/lower whiskers represent max/min value within 1.5 × 75th/25th interquartile range, respectively. N = 25 healthy individuals, 38 autoimmune individuals. G Neutralization capacity versus S1 RBD ELISA reactivity. Regression depicts the relationship between log(PRNT50) and S1 RBD ELISA for healthy participants, 95% C.I. shaded, regression line centered. Each dot represents a single individual. N = 25 healthy individuals, 38 autoimmune individuals. H S total ELISA reactivity (ng/ml) vs. S1 RBD ELISA reactivity (ng/ml), stratified by autoimmune disease status and medication category. ****p  <  0.0001, ***p  <  0.001 **p  <  0.01 and *p  <  0.05.
